OncLive Staff

In our exclusive interview, Dr. Markman shares the reasons why he dove into the gynecologic cancer space, what mottos he lives by in daily practice, and patient cases that have significantly impacted his career.

We recently traveled to Brooklyn, New York, for a State of the Science Summit™ on Gastrointestinal Cancer, which featured insights from Weill Cornell Medical Center and Montefiore Medical Center faculty.

OncLive interviewed experts at the State of the Science Summits™ in February 2020 on common misconceptions in their respective fields.

Kathryn E. Hudson, MD, and Jeff Yorio, MD, discuss when it is appropriate to wait for testing before starting therapy, the accuracy of tumor and liquid biopsies, as well as optimal sequencing strategies when managing patients with brain metastases.

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Lung Cancer, which featured insights from the UPMC and Fox Chase Cancer Center faculty.

The FDA has granted a priority review designation to a biologics license application for the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.

We traveled to Austin, Texas, for a State of the Science Summit™ on Precision Medicine, which featured insights from the Texas Oncology faculty.

OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.

Lecia V. Sequist, MD, MPH, and Zofia Piotrowska, MD, MHS, give their input on how they approach cases that are often encountered in clinic.

We traveled to Phoenix, Arizona, for a State of the Science Summit™ on Genitourinary Cancers, which featured insights from the Mayo Clinic and Benner MD Anderson Cancer Center faculty.

We traveled to Long Island, New York, for a State of the Science Summit™ on Breast Cancer, which featured insights from the NYU Langone’s Perlmutter Cancer Center faculty.

After witnessing 10 years of breakthroughs across the spectrum of cancer care, oncology experts are looking ahead as a new decade begins to capitalize on those wide-ranging therapeutic and diagnostic gains.

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

The FDA has approved olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma.

We traveled to Oklahoma City, Oklahoma, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the Stephenson Cancer Center faculty.

An application has been submitted to the FDA for selinexor for the treatment of patients with relapsed/refractory diffuse large B-Cell lymphoma who have received at least 2 prior multiagent therapies and who are ineligible for stem cell transplantation, including CAR T-cell therapy.

The FDA has approved enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.

Bristol-Myers Squibb has submitted a biologics license application to the FDA seeking approval of the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.

Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.

We traveled to Philadelphia, Pennsylvania, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the University of Pennsylvania faculty.

We traveled to Chicago, Illinois, for a State of the Science Summit™ on Lung Cancer, which featured insights from the University of Chicago faculty.

We traveled to Raleigh, North Carolina, for a State of the Science Summit™ on Breast Cancer, which featured insights from the Duke Cancer Institute faculty.

We sat down with Ajai Chari, MD, and Sundar Jagannath, MD, both of Mount Sinai Hospital, to provide insight on controversial, but critical, questions regarding the merits of quadruplet versus triplet therapy in the newly diagnosed setting, the optimal maintenance approach in high-risk patients, and the data in support of and against initiating treatment in patients with smoldering multiple myeloma.

We traveled to Salt Lake City, Utah, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from the University of Utah and Intermountain Healthcare.

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

The European Commission has approved the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma.

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the University of Pittsburgh Medical Center faculty.

Ruxolitinib met the primary endpoint of the phase III REACH2 trial, improving the overall response rate at day 28 versus best available therapy in patients with in patients with steroid-refractory acute graft-versus-host disease.

In keeping up with the expanding breast cancer treatment armamentarium, we sat down with Jane L. Meisel, MD, and Aditya Bardia, MD, MPH, who shed light on emerging treatment strategies for patients with metastatic triple-negative breast cancer and discussed the optimal timing of genomic testing in women with progressive hormone receptor–positive disease.

Patients with metastatic gastric or gastroesophageal junction cancer had improved overall survival with TAS-102, irrespective of prior gastrectomy.